Want to see TSE:ZEN full AI Analyst Report?
ZEN Stock Chart & Stats
C$0.77
-C$0.04(-5.13%)
At close: 4:00 PM EDT
C$0.77
-C$0.04(-5.13%)
Day’s Range― - ―
52-Week RangeC$0.52 - C$1.70
Previous CloseN/A
Volume182.49K
Average Volume (3M)66.24K
Market Cap
C$97.50M
Enterprise ValueC$60.34
Total Cash (Recent Filing)C$16.60M
Total Debt (Recent Filing)C$1.93M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding126,619,530
10 Day Avg. Volume86,681
30 Day Avg. Volume66,239
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)7.78
Price to Sales (P/S)459.28
P/FCF Ratio-13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLow leverage and a meaningful equity base provide financial flexibility to fund development and commercialization while reducing refinancing and solvency risk during the company’s early growth phase.
Government CommercializationA multiyear federal standing offer provides external validation and a potential route to recurring product adoption. Although modest in scale, it may support reference-customer credibility and future institutional sales.
Expanding IP PipelineAdditional patent protection can strengthen differentiation, support licensing discussions, and broaden Zentek’s addressable applications. If commercialized, the technology could add a higher-margin IP-based revenue stream beyond current products.
Bears Say
Minimal Declining RevenueVery low and declining revenue indicates that product-market adoption remains limited. This weak commercial base makes operating costs harder to absorb and leaves future funding dependent on uncertain sales growth, partnerships, or licensing.
Persistent LossesRecurring losses and unstable gross margins show that the business has not yet demonstrated a durable path to breakeven. Continued underperformance could erode equity and restrict the resources available for research and commercialization.
Ongoing Cash BurnPersistent operating and free-cash-flow deficits mean the company is not self-funding and may require additional capital to sustain development. This creates financing risk and could dilute shareholders if losses continue.
Zentek News
ZEN FAQ
What was Zentek’s price range in the past 12 months?
Zentek lowest stock price was C$0.52 and its highest was C$1.70 in the past 12 months.
What is Zentek’s market cap?
Zentek’s market cap is C$97.50M.
When is Zentek’s upcoming earnings report date?
Zentek’s upcoming earnings report date is Nov 16, 2026 which is in 77 days.
How were Zentek’s earnings last quarter?
Zentek released its earnings results on Aug 14, 2026. The company reported -C$0.018 earnings per share for the quarter.
Is Zentek overvalued?
According to Wall Street analysts Zentek’s price is currently Overvalued.
Does Zentek pay dividends?
Zentek does not currently pay dividends.
What is Zentek’s EPS estimate?
Zentek’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zentek have?
Zentek has 126,619,530 shares outstanding.
What happened to Zentek’s price movement after its last earnings report?
Zentek reported an EPS of -C$0.018 in its last earnings report. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of Zentek?
Currently, no hedge funds are holding shares in TSE:ZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zentek Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
13.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
60.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zentek
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Technical Analysis
Arch Biopartners
―
BioMark Diagnostics
―
Medexus Pharmaceuticals Inc
―
―
Sona Nanotech Inc
―